Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biora Therapeutics, Inc. - Common Stock (NQ: BIOR )

1.160 +0.010 (+0.87%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biora Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Submits Updated IND Application for BT-600
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Submit Updated IND Application for BT-600
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
Autonomous next-gen device exceeded performance targets in three recent preclinical studies 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Submission of IND Application to the U.S. FDA for BT-600 Program
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Reduces Debt and Largest Shareholder Increases Equity Exposure
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Progresses its BioJet™ Systemic Oral Delivery Platform
Confirmation of autonomous device function enables progress to testing of pharma collaborators’ molecules 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces New Patents Covering its BioJet™ Systemic Oral Delivery Platform
Intellectual property relates to key features of the company’s liquid jet injection technology 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Participate in Canaccord Genuity 43rd Annual Growth Conference
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Clinical Device Performance Study Results for its NaviCap™ Targeted Oral Delivery Platform
Phase 1-ready device shows 100% success in human functional study of twelve subjects to date 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces New Patents for its NaviCap™ Targeted Oral Delivery Platform
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the American Diabetes Association 83rd Scientific Sessions
An average bioavailability of 37% for a GLP-1 receptor agonist was achieved in animals 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces $8 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Present Preclinical Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Report First Quarter 2023 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Appoints Dr. Ariella Kelman as Chief Medical Officer
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Participate in Crohn’s & Colitis Foundation’s IBD Innovate Conference
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Bioavailability Results for Oral Delivery of GLP-1 Receptor Agonist
Preclinical data demonstrate potential to orally deliver peptides and monoclonal antibodies at bioavailability levels more than double the company’s current target 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Improved Bioavailability Results for its Systemic Delivery Platform
Average bioavailability greater than 50% with high consistency observed in animal study 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Presents Data from Device Performance Study with Repeat Doses in Both Fasted and Fed States at Crohn’s & Colitis Congress
Study demonstrates targeted delivery devices functioned as designed when administered with food, potentially enabling non-fasted administration 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Receives Pre-IND Feedback from FDA and Provides Update on Key Programs for 2023
Company is on track to move into the clinic with its lead targeted therapeutics program 
From Biora Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.